NCT04454476进行中（未招募）1 期
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 15
- 试验地点
- 3
- 主要终点
- Safety of Trametinib treatment: adverse events
研究概览
简要总结
This is a study of the safety and effectiveness of Trametinib treatment in patients who have received successful endoscopic submucosal resection of a Stage I gastric cancer.
详细描述
Objectives:
- To evaluate the efficacy of Trametinib in reversing metaplasia in participants with Stage 1 gastric cancer
- To evaluate the safety of Trametinibin in Stage I gastric cancer patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary registration
- •Person having intact stomach after treatment of early gastric cancer or gastric adenoma
- •Person whose treated gastric cancer histological type is intestinal type.
- •Person whose treated gastric cancer or gastric adenoma was curatively resected.
- •Person who does not have symptoms of gastric cancer recurrence.
- •Person who can declare agreement for enrollment by understanding the study and signing the informed consent document after hearing the explanation.
- •Person who can visit the hospital in accordance with the schedule.
- •Secondary registration
- •Person who has gastric atrophy at endoscopy.
- •Person who does not have symptoms of gastric cancer recurrence by endoscopy.
- •Person who has intestinal metaplasia in stomach, histologically confirmed in biopsy specimens taken under endoscopy within 8 weeks prior to taking MEK inhibitor, Trametinib.
排除标准
- •Person whose treated gastric cancer was diffuse or signet ring cancer.
- •Person whose treated gastric cancer or gastric adenoma was not curatively resected.
- •Person who has the history of other malignant disease.
- •Person who had a significant improvement in metaplasia after eradication therapy for Helicobacter pylori within one year.
- •Person who had plan of eradication Helicobacter pylori in 1 year 9 months
- •Person who has history of previous Trametinib or other MEK inhibitor use.
- •Person who has history of hypersensitivity to excipients.
- •Person who entered clinical trial and took investigational new drug within 12 weeks.
- •Presence of active infection other than chronic gastritis.
- •Cardiac conditions as follows:
- •Uncontrolled hypertension (BP>=150/95 mm Hg despite medical therapy)
- •Acute myocardial infection within 6 months prior to starting treatment
- •Uncontrolled Angina (Canadian Cardiovascular Society grade II-IV even after medication)
- •Symptomatic heart failure NYHA Class II-IV
- •<45% in the past
- •Severe valvular disease
- •<55% at present
- •Atrial fibrilation in ECG with BPM=>100 Laboratory values as listed below (SI units) Absolute Neutrophil Count <1.5x10A9/L (1500 per mm3) Platelets <100x10A9/L (100,000 per mm3) Hemoglobin<=9.0 g /dL Serum creatinine >1.5 X upper limit of normal (ULN) Serum bilirubin >1.5 x ULN AST or ALT > 2.5 x ULN
- •Ophthalmological conditions as follows:
- •Current or past history of retinal pigment epithelial detachment (RPED)/central serous retinopathy (CSR) or retinal vein occlusion Intraocular pressure (IOP) > 21 mmHg or uncontrolled glaucoma (irrespective of IOP)
- •Male or female patients of reproductive potential and, as judged by the investigator, are not employing an effective method of birth control and pregnant female.
- •Breast feeding female Have refractory nausea and vomiting , chronic gastrointestinal diseases (e.g . inflammatory bowel disease), or significant bowel resection that would adversely affect the absorption / bioavailability of the orally administered study medication.
- •Person who has history of hyperrefractory for Trametinib methyl sulfoxide Person who has pneumonia under chest X-ray. Have evidence of any other significant clinical disorder or laboratory finding that, as judgedby the investigator, makes it undesirable for the patient to participate in the study.
研究组 & 干预措施
Trametinib treatment
Experimental
干预措施: Trametinib treatment (Drug)
Trametinib treatment
Experimental
干预措施: Endoscopy (Procedure)
结局指标
主要结局
Safety of Trametinib treatment: adverse events
时间窗: About 12 weeks
Assessment of side effects induced during or after treatment with Trametinib.
Effectiveness of Trametinib in reversing metaplasia: changes in cell lineages
时间窗: About 12 months
The ability of Trametinib treatment to decrease the presence of metaplastic cell lineages in biopsies of the lining of the stomach, while also allowing the return of normal cell lineages (i.e. acid-secreting parietal cells). Cell lineages will be identified by immunostaining of tissue sections from biopsies.
次要结局
未报告次要终点
研究者
James Goldenring
Principal Investigator
Vanderbilt-Ingram Cancer Center
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney CancerRecurrent Renal Cell CancerStage IV Renal Cell CancerClear Cell Renal Cell CarcinomaNCT00408902National Cancer Institute (NCI)10
已完成
2 期
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorGISTNCT01874665Ariad Pharmaceuticals45
已完成
2 期
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell CancerNeoplasms, OralMouth NeoplasmsNCT01553851Washington University School of Medicine20
已完成
1 期
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibLung AdenocarcinomaLung Cancer MetastaticLung Cancer Stage IVRecurrent Lung AdenocarcinomaRecurrent Lung CancerLung CancerNCT03076164Memorial Sloan Kettering Cancer Center24
撤回
2 期
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)Gastrointestinal Stromal TumorsNCT02342600Sarcoma Alliance for Research through Collaboration